Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study

AIMS: We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of prevalent cardiovascular a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes Obes Metab
Glavni autori: Birkeland, Kåre I., Bodegard, Johan, Banerjee, Amitava, Kim, Dae Jung, Norhammar, Anna, Eriksson, Jan W., Thuresson, Marcus, Okami, Suguru, Ha, Kyoung Hwa, Kossack, Nils, Mamza, Jil Billy, Zhang, Ruiqi, Yajima, Toshitaka, Komuro, Issei, Kadowaki, Takashi
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756303/
https://ncbi.nlm.nih.gov/pubmed/32893440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14189
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items